How can the UK better use science and technology to create a more effective and efficient NHS and deliver more personalised medicine?
Individuals increasingly wish to play a central role in their own health and care, whilst rapid advances in bioscience and technology are providing expanding opportunities to deliver more personalised care. Together, these developments call for changes in the practice of medicine and public health, but the rate of translation from ideas and research into healthcare is often frustratingly slow.
The APPG on Personalised Medicine provides a forum to explore not only new and exciting medical innovations, but also the barriers to and complexities of implementation in the NHS, in an effort to identify solutions. The Group will help ensure that patients see the health benefits of the nation’s huge investment in these fields.
This APPG is designed to:
- Examine the potential of new and emerging scientific research and technologies to shape and improve future health and care
- Ensure that the fruits of investment and innovation in the life sciences are adopted in the NHS for the benefit of patients and the wider public
- Work towards the creation of a sustainable health service for the 21st century and beyond by realising the transformative power of personalised medicine driven by bioscience and technology
Personalised medicine for lung cancer (AGM)
Lung cancer is an area of serious unmet clinical need, with just 5% of patients surviving for 10 years or more. But new technologies are increasingly challenging these statistics by providing more tailored diagnosis, treatment and care.
Parliamentarians and diverse stakeholders will meet to discuss the needs of lung cancer patients, examine new opportunities for more personalised medicine and care, and explore barriers to progress towards better patient experience and outcomes.
Personalised medicine for common disease
This Group will examine new uses of sciences and technology that may offer significantly better and more personalised care outside the most advanced areas of clinical application by examining selected major common diseases.
According to the British Heart Foundation, cardiovascular disease affects around seven million people and accounts for just over a quarter of all deaths in the UK. In consultation with experts and stakeholders in the field, this Group will assess how far personalised medicine can help patients and the NHS cope with cardiovascular disease.
Public Health England data for 2016 showed that 3.8 million people in the UK suffer from diabetes with the more common form Type 2 diabetes already costing the NHS £8.8 billion per year. Building on findings from the cardiovascular disease work, the APPG will consider the prospects for personalised medicine in diabetes to address unique needs with respect to prevention, management and improved outcomes.
The findings from investigations into these disease areas, with particular emphasis on any common themes or issues that may arise, will inform the Group’s future projects. Wherever possible we will collaborate with other APPGs on issues of mutual interest and remain flexible to respond to developments in health, science and technology.
Read the full work programme for 2017-18 here
This APPG is wholly committed to ensuring transparency across all its activities, membership and funding.
As an official All-Party Parliamentary Group, we encourage policy-making that supports innovation in healthcare for better patient and population health and care. We do not endorse, support, lobby for or campaign on behalf of one organisation.
The APPG on Personalised Medicine operates according to a strict Code of Governance. This Group and its work are driven solely by our Parliamentary members.
As an independent health policy think tank, the PHG Foundation provides the Secretariat for this APPG.